Prawo i regulacje · 07/05/2021

FDA Approves New Drug for Attention Deficit Hyperactivity Disorder, Schedules it as Controlled Substance

The US FDA approved AZSTARYS, a combination drug containing serdexmethylphenidate, for treating ADHD in patients 6 years and older, and the DEA has placed it in Schedule IV of the Controlled Substances Act, allowing its commercial distribution.